What Is Retatrutide and When Could Weight-Loss Drug Be Publicly Available?
Newsweek reports that an Eli Lilly-funded phase 3 trial of retatrutide, an experimental injectable drug targeting three hormone receptors, studied 2,339 adults with obesity without diabetes over 18 months. Average weight reduction ranged from 17.6 percent at the 4-milligram dose to 25 percent at the 12-milligram dose, versus 3.9 percent on placebo. The drug is not FDA approved, and Newsweek also covers black-market sales.
Why it matters: Relevant to Maryland adults with obesity exploring medical weight-loss options, including those with knee osteoarthritis or sleep apnea, and to clinicians who refer them.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to newsweek.com. October 14, 2026.
